A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

NCT04951635 PHASE3 RECRUITING

To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).

Details

Lead sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase	PHASE3
Status	RECRUITING
Enrolment	150
Start date	Thu Mar 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 15 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-small Cell Lung Cancer

Interventions

• Almonertinib
• Placebo Almonertinib

Countries

China